Pfizer has entered into an agreement to acquire PowderMed Ltd., a UK-based company specializing in the emerging science of DNA-based vaccines. PowderMed has developed a technology to deliver DNA directly to the cells of the body’s immune system and is advancing a promising pipeline of vaccine candidates for influenza and chronic viral diseases. “This acquisition is a strategic opportunity to enter the vaccine market and is part of our focus on broadening healthcare solutions for...